Pierach C A, Bossenmaier I, Cardinal R, Weimer M, Watson C J
Klin Wochenschr. 1980 Aug 15;58(16):829-32. doi: 10.1007/BF01491103.
We report our experience with hematin in the treatment of 57 patients in porphyric attacks. The ratio of acute intermittent porphyria: variegate porphyria: hereditary coproporphyria was 43:11:3. More than 90% of the patients showed not only a decline in their porphyrin precursors, but also a favor able clinical response. Hematin was well tolerated and should be considered the treatment of choice in porphyric relapse.